Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03059576
Other study ID # 2017ES00002
Secondary ID
Status Completed
Phase N/A
First received February 13, 2017
Last updated March 23, 2017
Start date December 2012
Est. completion date February 2017

Study information

Verified date March 2017
Source Universidad de Murcia
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this investigation is to assess the role of the genetic and environmental factor on circadian system, in free living conditions by the use of a female twin population. With the results from this study, the investigators expect to advance in the understanding of the role of the endogenicity of the circadian system variables such as temperature, activity, sleep and timing of food intake as the main cause of the coincidence of the rhythms. However, the investigators expected that some parameters are still dependent on environment to a relevant extent and, hence, amenable to change through external interventions.


Description:

Twin studies are a classic in the analysis of the relative contribution of genetic and environmental factors to behavior and other phenotypes. These models are most often used to separate genetic from environmental causes in the family resemblance methodology. These models based on twins have been previously carried out in chronobiology. In fact, during the years 1993 and 1994, Paul Linkowski et al., performed two relevant studies on the circadian system to analyze the relative contributions of hereditary and/or environmental factors of cortisol secretion and blood pressure, respectively, and concluded that genetic factors control some of the characteristics of cortisol and diastolic blood pressure circadian rhythmicity. The heritability of other circadian markers has also demonstrated such as morningness- eveningness (44%), sleep-related variables have also pointed to a relevant role of genetics with heritability estimates of sleep duration between 17% and 55%. However, to the investigators knowledge, the heritability of other relevant chronobiological markers, measured in free living conditions such as body temperature, actigraphy and sleep has not been studied.

These goals will be achieved through a specific approach:

- Observational (Aim 1): To study the potential effect of the genetic and environmental factor in the circadian system health in order to improve the chronobiological therapies in the clinical practice (n=106).


Recruitment information / eligibility

Status Completed
Enrollment 106
Est. completion date February 2017
Est. primary completion date March 2013
Accepts healthy volunteers
Gender Female
Age group 18 Years to 70 Years
Eligibility IInclusion Criteria:

- Body Mass Index: >19 kg/m2

- Age: between 18 and 70 year of age

- Caucasian

Exclusion Criteria:

- Receiving treatment with thermogenic, lipogenic, or contraceptive drugs

- Diabetes mellitus, chronic renal failure, hepatic diseases, or cancer diagnosis

- Bulimia diagnosis, prone to binge eating

- Undergoing treatment with anxiolytic or antidepressant drugs

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Chronobiological status of the subjects
Participation was completely voluntary and not remunerated. The subjects were organized into groups of 5 pairs, and were given an appointment at a university facility located in the city center, where informed consent was signed prior to the procedures indicated below. An informational letter was sent to pre-selected individuals. Later a phone call confirmed their availability. Temperature rhythm was assessed continuously for 7 days using a temperature sensor and programmed to collect information every 10 min. Body position and rest-activity rhythm were assessed over the same 7 days using a Acceleration Data Logger that record data every min and placed on the non-dominant arm by means of an elastic band, with its X axis parallel to the humerus bone. Diet and sleep record were completed over the same week, their sleep schedules and their nutritional status.

Locations

Country Name City State
Spain Juan Ramón Murcia

Sponsors (1)

Lead Sponsor Collaborator
Universidad de Murcia

Country where clinical trial is conducted

Spain, 

References & Publications (2)

Lopez-Minguez J, Colodro-Conde L, Bandín C, Ordoñana JR, Garaulet M, Madrid JA. Application of multiparametric procedures for assessing the heritability of circadian health. Chronobiol Int. 2016;33(2):234-44. doi: 10.3109/07420528.2015.1130051. Epub 2016 Jan 28. — View Citation

Lopez-Minguez J, Ordoñana JR, Sánchez-Romera JF, Madrid JA, Garaulet M. Circadian system heritability as assessed by wrist temperature: a twin study. Chronobiol Int. 2015 Feb;32(1):71-80. doi: 10.3109/07420528.2014.955186. Epub 2014 Sep 10. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Sleep Duration Sleep duration will be computed from self-reported Total of 1 week between Visit 1 and 2
Other Total Energy Intake Total energy intake in kcal/day will be computed from 7-day 24-hr dietary recalls Total of 1 week between Visit 1 and 2
Other Dietary Composition Macronutrient and micronutrient intake will be computed from 7-days of self-reported 24-hr dietary recalls Total of 1 week between Visit 1 and 2
Other Dietary Intake Timing Food timing will be self-reported and averaged across 7-days of 24-hr dietary recalls Total of 1 week between Visit 1 and 2
Other Chronotype Assessed using the Morningness-Eveningness Questionnaire Total of 1 week between Visit 1 and 2
Primary Temperature record Measured using temperature sensor Total of 1 week between Visit 1 and 2
Primary Actigraphy record Measured using Pendant Acceleration Data Logger Total of 1 week between Visit 1 and 2
Secondary Light record Measured using Pendant Acceleration Data Logger Total of 1 week between Visit 1 and 2
Secondary Sleep record Measured using Pendant Acceleration Data Logger Total of 1 week between Visit 1 and 2
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1